22:04 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Mouse studies suggest inhibiting tumor-associated macrophages (TAMs) with liposomal clodronate could help treat lung cancer. In a mouse model of Lewis lung carcinoma, a liposomal preparation of the bisphosphonate clodronate, which induces...
07:00 , Sep 19, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of skin rash syndrome caused by anti-epidermal growth factor receptor (EGFR) therapy A mouse model of anti-EGFR therapy-induced skin rash syndrome could be...
07:00 , May 27, 2013 |  BioCentury  |  Strategy

Royalty pain or gain

Elan Corp. plc shareholders have a lot to consider before a June 17 meeting to decide the fate of the biotech. Investors can walk away after pocketing the $6.4 billion proposed by suitor Royalty Pharma...
07:00 , Jun 7, 2010 |  BC Week In Review  |  Clinical News

Zometa zoledronic acid: Phase III data

In the Phase III Myeloma IX Study in 1,960 evaluable patients, Zometa significantly reduced the proportion of patients experiencing an SRE vs. Bonefos clodronate (27% vs. 35.3%, p=0.0004). Additionally, Zometa significantly improved OS (50 vs....
07:00 , Apr 3, 2006 |  BC Week In Review  |  Clinical News

Bonefos clodronate cancer data

Data from a double-blind trial in 555 evaluable patients showed that oral Bonefos plus standard adjuvant therapy significantly reduced the occurrence of bone metastases within the first 5 years post-surgery. At 2 years, serum propeptides...
07:00 , May 16, 2005 |  BC Week In Review  |  Clinical News

Bonefos clodronate regulatory update

An FDA decision about an NDA for Bonefos clodronate as an adjuvant treatment for reducing the occurrence of bone metastases in stage II/III breast cancer patients will be delayed. At a recent meeting, FDA indicated...
00:45 , May 12, 2005 |  BC Extra  |  Company News

FDA wants more Bonefos data

Schering (FSE:SCH;SHR) said an FDA decision about an NDA for Bonefos clodronate as an adjuvant treatment for reducing the occurrence of bone metastases in stage II/III breast cancer patients will be delayed. At a recent...
08:00 , Jan 10, 2005 |  BC Week In Review  |  Clinical News

Bonefos clodronate regulatory update

FDA issued an approvable letter for Bonefos clodronate, an oral non-amino bisphosphonate, which is indicated to reduce the occurrence of bone metastases in the post-surgical (adjuvant) treatment of breast cancer patients. SCH's subsidiary Berlex Laboratories...
08:00 , Jan 7, 2005 |  BC Extra  |  Company News

Berlex gets approvable letter for Bonefos

Berlex received an approvable letter from FDA for Bonefos clodronate as an adjuvant treatment for reducing the occurrence of bone metastases in stage II/III breast cancer patients. The company said it will request a meeting...
08:00 , Nov 8, 2004 |  BC Extra  |  Company News

Bonefos ODAC meeting cancelled

Schering (FSE:SCH; SHR) subsidiary Berlex Laboratories said the FDA cancelled the Dec. 2 meeting at which the Oncology Drugs Advisory Committee was to discuss an NDA for Bonefos clodronate . The compound is under review...